Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

So, the natural question for B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2019, B.R.A.I.N. Biotechnology Research and Information Network had cash of 15m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through 5.4m. That means it had a cash runway of about 2.8 years as of June 2019. Notably, however, analysts think that B.R.A.I.N. Biotechnology Research and Information Network will break even (at a free cash flow level) before then. If that happens, then the length of its cash runway, today, would become a moot point. You can see how its cash balance has changed over time in the image below.

XTRA:BNN Historical Debt, December 2nd 2019

It was fairly positive to see that B.R.A.I.N. Biotechnology Research and Information Network reduced its cash burn by 39% during the last year. And considering that its operating revenue gained 45% during that period, that's great to see. We think it is growing rather well, upon reflection. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

We are certainly impressed with the progress B.R.A.I.N. Biotechnology Research and Information Network has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of 175m, B.R.A.I.N. Biotechnology Research and Information Network's 5.4m in cash burn equates to about 3.1% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

Story continues

It may already be apparent to you that we're relatively comfortable with the way B.R.A.I.N. Biotechnology Research and Information Network is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. And even though its cash burn reduction wasn't quite as impressive, it was still a positive. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Taking all the factors in this report into account, we're not at all worried about its cash burn, as the business appears well capitalized to spend as needs be. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the B.R.A.I.N. Biotechnology Research and Information Network CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See original here:
We're Not Worried About B.R.A.I.N. Biotechnology Research and Information Network's (ETR:BNN) Cash Burn - Yahoo Finance

The 29 rating InvestorsObserver gives to Bellerophon Therapeutics Inc (BLPH) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 15 percent of stocks in the Biotechnology industry, BLPHs 29 overall rating means the stock scores better than 29 percent of all stocks.

Click Here to get the full Stock Score Report on Bellerophon Therapeutics Inc (BLPH) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 29 means the stock is more attractive than 29 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Bellerophon Therapeutics Inc (BLPH) stock is down -12.66% while the S&P 500 is up 0.09% as of 2:35 PM on Wednesday, Dec 18. BLPH is down -$0.05 from the previous closing price of $0.38 on volume of 1,539,662 shares. Over the past year the S&P 500 is higher by 25.50% while BLPH is down -66.67%. BLPH lost -$0.15 per share the over the last 12 months.

To screen for more stocks like BLPH click here.

Original post:
Is Bellerophon Therapeutics Inc (BLPH) Stock a Good Buy in Biotechnology - InvestorsObserver

Biomarker Technologies Market Report fulfill the Current as well as Future aspects and trends. The market study on Global Biomarker Technologies Market 2019 Research Report studies Deep analysis of the Biomarker Technologies Market primarily based upon factors on which the companies compete in the market, key trends and segmentation analysis.

Global Biomarker Technologies Industry study deals with a complete overview of the Report, which consists of definitions, a wide range of statements and an entire chain structure. The global Biomarker Technologies business analysis moreover consists of the resourceful landscape, development history and important development drift presented by Biomarker Technologies industry. Biomarker Technologies trade introduces more extensive guidelines for high growth potential industries professional survey with Insight analysis. Further, the Biomarker Technologies Industry research report also covers key players profiling with financial facts and key developments of products or service.

Top Key Players profiled in this report:Zhongyu gold mark (Beijing) biotechnology Limited by Share Ltd, Shanghai Jie Yi Biotechnology Co. Ltd., Hua Zhi rice Biotechnology Co. Ltd., Jiangsu Junkai biology

Get FREE SAMPLE Copy of Report here:http://www.marketresearchstore.com/report/global-biomarker-technologies-market-report-2019-661795#RequestSample

Global Biomarker Technologies Market report contains more than 101 pages which highly exhibit on current market analysis, trends, upcoming as well as future opportunities, pricing, and profitability. The report can answer questions about these market developments and also the scope of competition, cost. The faster-growing and leading segments operational in the market have been expansively studied based on several major factors.

Report Highlights:

The Given Research Report is segmented into various region such as: United States, EU, China, Japan, Southeast Asia and India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:Solid Biopsy, Liquid Biopsy

On the basis of the end users/applications:Biomarker Identification, Validation & Development, Routine Biomarker-Based Tests

Get Inquiry For Buying:http://www.marketresearchstore.com/report/global-biomarker-technologies-market-report-2019-661795#InquiryForBuying

Reasons to Invest in This Global Biomarker Technologies Market Report:

Global Biomarker Technologies Market Study Report 2019 also provides brief details As:

The Biomarker Technologies report offers a close summary of the key segments within the market. The quickest & slowest growing market segments are lined during this report. This analysis report covers the expansion prospects of the worldwide market based on end-users.

Read Full Indexed Global Market Report:http://www.marketresearchstore.com/report/global-biomarker-technologies-market-report-2019-661795

In the end, the report includes Biomarker Technologies new project SWOT analysis, investment practicableness analysis, investment come analysis and development trend analysis. This report additionally presents product specification, producing method, and products cost structure. Production is separated by regions, technology and applications.

This post was originally published on Market Reports Observer

Read more:
Global Biomarker Technologies Market 2019 Competitive Analysis by- Zhongyu gold mark biotechnology Limited by Share Ltd - Market Reports Observer

Biotechnology, often abbreviated to biotech, is the area of biology that uses living processes, organisms or systems to manufacture products or technology intended to improve the quality of human life. Depending on the technology, tools and applications involved, biotechnology can overlap with molecular biology, bionics, bioengineering, genetic engineering and nanotechnology.

By harnessing cellular and biomolecular processes, scientists can make advances and adaptations to technology in various fields. Traditional processes include using living organisms in their natural form, breeding new living organisms or modifying their genetic makeup. Successful applications of such processes have resulted in treatment of disease, environmental impact reduction and more efficient use of natural resources. Major biotech companies implement biotechnology as a practice to bring medical devices and products to the mainstream market.

Biotechnology, like other advanced technologies, has the potential for misuse. Concern about this has led to efforts by some groups to enact legislation restricting or banning certain processes or programs, such as human cloning and embryonic stem-cell research. There is also concern that if biotechnological processes are used by groups with nefarious intent, the end result could be biological warfare.

The science of biotechnology can be broken down into sub-disciplines based on common uses and applications.

Modern biotechnology can be used for a variety of applications, including:

See the article here:
What is biotechnology (biotech)? - Definition from WhatIs.com

The Biotechnology graduate program offers Masters (Sc.M. & A.M.) and Ph.D. degrees and is designed for students interested in a range of topics related to the field of biotechnology including drug & gene delivery, drug discovery and cell therapy. Faculty have active research in one or more of these three areas. The educational objectives of the program are to promote an understanding of: 1.) the designs and materials used in novel cell and drug delivery systems; 2.) the molecular, cellular and animal sciences of drug discovery & drug development; and 3.) the development and testing of cell-based therapies for the treatment of diseases. We also offer courses on the business and management of biotechnology.

Ph.D. Application Deadline: First week in January

Ph.D. Recruitment Day: TBD

External Masters Application Deadlines: November 15 (Spring start) and April 15 (Fall start)

For general information about graduate programs at Brown, visit the following websites: Graduate School, Applying to Brown, and Financial Support.

See more here:
Biotechnology Graduate Program | Department of Molecular ...

Biotechnology can be defined as the controlled and deliberate manipulation of biological systems (whether living cells or cell components) for the efficient manufacture or processing of useful products. The fact that living organisms have evolved such an enormous spectrum of biological capabilities means that by choosing appropriate organisms it is possible to obtain a wide variety of substances, many of which are useful to man as food, fuel and medicines. Over the past 30 years, biologists have increasingly applied the methods of physics, chemistry and mathematics in order to gain precise knowledge, at the molecular level, of how living cells make these substances. By combining this newly-gained knowledge with the methods of engineering and science, what has emerged is the concept of biotechnology which embraces all of the above-mentioned disciplines.

Biotechnology has already begun to change traditional industries such as food processing and fermentation. It has also given rise to the development of a whole new technology for industrial production of hormones, antibiotics and other chemicals, food and energy sources and processing of waste materials. This industry must be staffed by trained biotechnologists who not only have a sound basis of biological knowledge, but a thorough grounding in engineering methods. At Dublin City University, the School of Biological Sciences is unique in having, as members of its academic staff, engineers who have specialised in biotechnology. The degree programme also places a major emphasis on practical work and on developing a wide range of analytical and manipulative skills, including pilot plant operational skills appropriate to the biotechnologist. Graduates will be in an ideal position to exploit the opportunities for biotechnology in Ireland, in established or developing companies.

The course encompases biological and engineering aspects

For more information on the BSc in Biotechnology

Read more here:
What is Biotechnology? | School of Biotechnology | DCU

Biotechnology is the science that exists at the intersection where the natural, living world meets market demands for products useful to the human species. Biotechnology specialists work in several key areas, including medicine, agriculture, food technology, biological engineering, biodegredation and education. With a PhD in Biotechnology, a graduate is highly qualified to work in a supervisory position at a number of publicly and privately funded organizations, laboratories, companies and institutions. Furthermore, a PhD in Biotechnology program will press candidates to take on intellectual and professional challenges that will prepare them for success in tackling any problem in their working careers.

PhD in Biotechnology programs are offered by universities and institutions of higher learning all across the world, from Malaysia to the USA. PhD candidates generally work for several hours in the laboratory, but also balance this time with teaching or assisting professors, writing or collaborating on scholarly articles and assisting colleagues with other research projects. Through independent research culminating in a dissertation, which is peer-reviewed and published, PhD in Biotechnology candidates are given the opportunity to pursue their own research interests and enhance their practical knowledge in a supportive, well-facilitated setting.

To learn more about the opportunities for enrolling in a PhD in Biotechnology, simply scroll down and click to read more.

Original post:
Best PhD Degrees in Biotechnology 2018

State-of-the-art labs: Much of the required course work will be offered at the Center for Plant and Life Sciences. These state of the art laboratory facilities are located within BioResearch and Development Growth (BRDG) Park, 1005 North Warson Road, Creve Couer MO 63132.

Associate in Applied Science (AAS) degree blends general education requirements with specialized biotechnology laboratory training.

Certificate of Specialization (CS) is for those students already possessing a Bachelors degree in a life science field. This certificate will provide the hands-on laboratory skills piece that they may be missing from a four year degree program.

Hands-on experience:If you areseeking an AAS degree,you will benefit from a workplace learninginternship. These internships are usually fulfilled on site at the Center for Plant and Life Sciences where much of the upper level course work is taught, or at an Industry Partners location. For more information on the different types of workplace learning experiences that might be available at any given time, contact Elizabeth Boedeker (eboedeker@stlcc.edu; 314 513-4966).

More than one million studentshave attended STLCC. Its the largest institute of higher education in the region and the second largest in Missouri.

Our instructors worked for industry giants like Monsanto and Sigma-Aldrich and bring that experience to the classroom. Students will learn from seasoned professionals who offer one-on-one coaching, extended office hours and opportunities for extra lab practice.

Students practice lab techniques on millions of dollars worth of equipment covering a variety of bioscience niches the same equipment used by researchers at BRDG Park.

This program is designed to flexible for both full-time day students as well as those students in careers who need evening classes.

The gainful employment regulation requires nondegree programs at community colleges to meet minimum thresholds with respect to the debt-to-income rates of their graduates. You can view the information for this program here as reported to the Department of Education.

Excerpt from:
Biotechnology - stlcc.edu

TEL AVIV, Israel, Aug. 21, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 30, 2017.

"We are very pleased with our accomplishments in the first half of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. "As planned, 2017 is turning into a transformative year for Cellect Biotechnology. Cellect initiated its Phase I/II study on cancer patients undergoing matched related allogeneic HSCT transplantation and reported positive results in the first patient followed by the approval to recruit two more patients. Further, Cellect held a pre-IND meeting with the FDA that was very positive and Cellect is moving ahead with its plan to submit an IND".

Important progress was achieved with the company's IP portfolio the major patent covering the composition of matter and use of the ApotainerTm was issued in US and Russia, the collaboration with Entegris was further consolidated by receiving a BIRDF non-equity grant, and the development of the Apotainer was accelerated.

In addition, world renowned leaders joined the Company (i.e KOLs from Harvard Medical school, executives from Pfizer and Merck) and the Company teamed up with Boston based Locust-Walk business development group for planning and launching a business development campaign before the end of the year.

During the second quarter, the Company made the following announcements -

Recent Corporate Highlights:

Second Quarter 2017 Financial Results:

Balance Sheet Highlights:

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2017 (U.S. $1 = NIS 3.496).

The Company's consolidated financial results for the three and six months ended June 30, 2017 are presented in accordance with International Financial Reporting Standards.

About Cellect Biotechnology Ltd.

The Company is developing an innovative technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. This functional-based selection is a breakthrough technology in the ability to isolate stem cells from any given tissue, and may improve a variety of stem cells applications.

The Company's first planned product line is expected to include unique containers for cell selection in an apoptosis-inducing microenvironment. Cellect's first planned commercial product candidate is a medical kit designed for the cancer treatment bone marrow transplantations market, as well as other markets which require cell selection. The Company plans that in the future its technology will be integrated in many production procedures of stem cell-based products.

The Company's securities are currently traded on both the NASDAQ Capital Market and the Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP").

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our anticipated performance in 2017, the expected characteristics of our first product line, our beliefs about the future integration of our technology into the production procedures of stem cell-based products and the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2017

2017

2016

2017

2016

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

1,495

5,227

3,679

2,405

1,848

General and administrative expenses

1,729

6,046

3,547

3,497

1,617

Other income

-

-

(280)

-

(280)

Operating loss

3,224

11,273

6,946

5,902

3,185

Financial expenses (income) due to warrants exercisable into shares

1,519

5,312

-

(1,461)

-

Other financial expenses (income), net

135

468

23

161

(5)

Total comprehensive loss

4,878

17,053

6,969

4,602

3,180

Loss per share:

Basic and diluted loss per share

0.045

0.158

0.088

0.042

0.039

Weighted average number of shares outstanding used to compute basic and diluted loss per share

108,034,218

108,034,218

79,113,097

108,462,728

81,456,571

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

Go here to read the rest:
Cellect Biotechnology Ltd Provides Corporate Update and Reports ... - Markets Insider

Evotec's immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification of antigens that specifically induce a T regulatory cell response in inflammatory and auto-immune disorders.

Using the company's nanoparticle platform, the collaboration will initially focuson identification of inflammatory or autoimmunity-inducing antigens that trigger immune tolerance through activation of regulatory T cells responses in liver stem cells. Specifically, Topas targets peptide-loaded nanoparticles towards liver sinusoidal endothelial cells (LSECs), which are one of the body's premier sites to induce tolerance against bloodborne antigens by generating peptide-specific regulatory T cells.

Under the terms of the agreement, Topas will be responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. According to the contract, Lilly may licence and advance development of all candidates originating from the collaboration. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly. Financial details of the collaboration have not been disclosed.

Topas Therapeutics was spun out in March from Evotec's subsidiary Bionamics GmbH. The company, which uses a groundbreaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen-specific immune tolerance in the liver, has14m of venture capital fromEpidarex Capital, EMBL Ventures and Gimv in its pockets. Evotec is its largest shareholder.

Topas has several candidate peptides under preclinical development, the most advanced expected to come to the clinic in 2018 is intended to treat multiple sclerosis.

Read more here:
Topas Therapeutics lands option deal with Eli Lilly - European Biotechnology

Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle.

Anaeropharma Science is based in Tokyo. It develops novel genetically enhanced bacteria to fight tumours. The companys lead product APS001F is based on an obligate anaerobic bacterium. Bifidobacterium longum can only proliferate in the hypoxic core of solid tumours, where it secretes the enzyme cytosine deaminase turning a systemically administered prodrug into a cytotoxic agent, which hollows out the tumour from the inside. The company is currently conducting a Phase Ib/IIa trial of APS001F in patients with advanced solid tumours in the USA. Lead investor Seventure points out that the investment of US$13.2m (11.6m) will strengthen a Japanese leader in the microbiome sector. Anaeropharma will use the financing to accelerate the development of multiple programmes based on its proprietary platform technology.

Seventure Partners invests alongside Novartis Pharma and Japanese investors Shinsei Corporate Investment Limited, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital. This is Seventures first investment in a Japanese company, the Paris-based venture capital firm declared. There is a huge market opportunity for novel treatments that harness the specific capabilities of microbiome-derived bacteria. Anaeropharma Science is developing a pioneering approach to the cancer therapy, which may powerfully complement other axes of modern oncology research, said Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners. The Companys innovative R&D is a great fit for our Health For Life Capital investment vehicle. Eric de La Fortelle, Venture Partner at Seventure Partners, will have a Board observer seat in the company.

In the life sciences, Seventure focuses on four areas of interest, including the investment topic microbiome, nutrition, foodtech and personalised medicine. Investments can range between 500k and 10m per round, or up to 20m per company, from early to late stage.

See original here:
Seventure debuts in Japan with microbiome investment - European Biotechnology

Welcome to your weekly digest of approaching regulatory and clinical readouts. Puma's (NYSE:PBYI) neratinib, or Nerlynx, has a PDUFA date set for July 21, and with a positive panel review behind it the focus turns to its potential label and commercial outlook. Its market could be disrupted by Roche's (OTCQX:RHHBY) Perjeta.

Meanwhile, the next test for Novo Nordisk's (NYSE:NVO) semaglutide will be its head-to-head trial against Lilly's Trulicty, the prospective market leader. The data could help differentiate the GLP-1 market, and with semaglutide boasting a cardiovascular benefit it could carve out some market share.

Puma hopes for roaring approval

Nerlynx's May panel meeting resulted in a 12-4 vote - a strong but not overwhelming endorsement. The project was filed for adjuvant treatment of Her2-positive breast cancer, but its diarrhoea side effect is well known, and many panel members urged a narrower patient population than Puma's application seeks (Puma pulls within sight of FDA OK, May 24, 2017).

Should the regulators follow the panel recommendation Nerlynx still faces a big commercial challenge in the shape of Roche's Perjeta, though ultimately the Aphinity study of the Swiss company's drug disappointed. Aphinity data unveiled at Asco showed Perjeta plus Herceptin giving a statistically significant but unimpressive one percentage point reduction in risk of progression over Herceptin alone in adjuvant use.

However, as Perjeta is already on the market for treatment and neoadjuvant use in combination with Herceptin, oncologists could begin prescribing it off-label in the adjuvant setting.

With Perjeta's own FDA decision for adjuvant use still months away, Roche's sales representatives are not allowed to talk about it until approval, unless doctors ask them (Asco - Aphinity and Roche's 1% solution, June 5, 2017).

Puma will therefore have to think hard about its pricing strategy, but as a small molecule Nerlynx could come in cheaper than Roche's combination of two biologicals. However, associated costs of Nerlynx's diarrhoea side effect will have to be taken into consideration.

Sustaining its position

The phase III Sustain 7 trial of semaglutide tests the Novo Nordisk project versus Trulicity as an add-on to metformin in 1,201 type 2 diabetics. Two subcutaneous doses of each were tested: 0.5mg or 1.0mg of semaglutide per week, versus Trulicity at 0.75mg or 1.5mg per week.

The primary measure was change in glycosylated hemoglobin, also known as HbA1c, at week 40; results are due in the third quarter.

Novo will be going for superiority, and judging by previous studies with the two drugs it has a chance of getting it. Looking across trials semaglutide has shown slightly greater reductions in HbA1c than those achieved by Trulicity in similar add-on settings.

Sustain 7 results are important as they could differentiate the weekly GLP-1s. Trulicity is set to be the leader by 2022, according to consensus from EvaluatePharma, while injectable Semaglutide sits in third place.

Semaglutide could claw back some market share as it has shown a cardiovascular benefit, something that Trulicity has yet to do, at least until results from Trulicity's Rewind cardiovascular outcomes study come out next year (Semaglutide heart data spice up once-weekly GLP-1 race, April 28, 2016).

Injectable Semaglutide was filed in the US last December, so FDA action could come at the end of the year; an oral version is in phase III trials, with data due in 2018.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

See the original post:
Puma's FDA Decider And Semaglutide's Head-To-Head Battle - Seeking Alpha

SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. ("Vir") (Nasdaq: VIR) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir's proprietary antibodies. WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. If the antibodies receive regulatory approvals, WuXi Biologics has the rights to commercialize therapies in Greater China, and Vir has the rights to commercialize therapies in all other markets worldwide.

Vir has identified a number of monoclonal antibodies (mAbs) that bind to SARS-CoV-2. These antibodies were isolated from individuals who had survived a Severe Acute Respiratory Syndrome (SARS) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

"We are acutely aware of the importance of moving rapidly in response to COVID-19," said George A. Scangos, Ph.D., CEO of Vir Biotechnology. "In the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat."

"Both WuXi Biologics and Vir felt the great urgency to develop antibodies to treat global patients provided they work in the clinic. Our state-of-the-art technology platform and robust global-quality supply network make us uniquely qualified in expediting the development and manufacturing of these potential treatments," commented Chris Chen, Ph.D., CEO of WuXi Biologics. "Once again WuXi Biologics is collaborating with global biotech companies such as Vir to expedite biologics development to benefit patients worldwide."

About Vir's Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in the Democratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit http://www.wuxibiologics.com.

SOURCE WuXi Biologics

Go here to see the original:
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 - Yahoo Finance

Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle.

Anaeropharma Science is based in Tokyo. It develops novel genetically enhanced bacteria to fight tumours. The companys lead product APS001F is based on an obligate anaerobic bacterium. Bifidobacterium longum can only proliferate in the hypoxic core of solid tumours, where it secretes the enzyme cytosine deaminase turning a systemically administered prodrug into a cytotoxic agent, which hollows out the tumour from the inside. The company is currently conducting a Phase Ib/IIa trial of APS001F in patients with advanced solid tumours in the USA. Lead investor Seventure points out that the investment of US$13.2m (11.6m) will strengthen a Japanese leader in the microbiome sector. Anaeropharma will use the financing to accelerate the development of multiple programmes based on its proprietary platform technology.

Seventure Partners invests alongside Novartis Pharma and Japanese investors Shinsei Corporate Investment Limited, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital. This is Seventures first investment in a Japanese company, the Paris-based venture capital firm declared. There is a huge market opportunity for novel treatments that harness the specific capabilities of microbiome-derived bacteria. Anaeropharma Science is developing a pioneering approach to the cancer therapy, which may powerfully complement other axes of modern oncology research, said Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners. The Companys innovative R&D is a great fit for our Health For Life Capital investment vehicle. Eric de La Fortelle, Venture Partner at Seventure Partners, will have a Board observer seat in the company.

In the life sciences, Seventure focuses on four areas of interest, including the investment topic microbiome, nutrition, foodtech and personalised medicine. Investments can range between 500k and 10m per round, or up to 20m per company, from early to late stage.

The rest is here:
Seventure debuts in Japan with microbiome investment - European ... - European Biotechnology

Southern Africa is on the receiving end of the devastating impact of climate change, driving millions into hunger.

A record 45 million people mostly women and children in the 16-nation Southern African Development Community are gravely food insecure following repeated drought, widespread flooding and economic disarray, according to the WFP.

Countries like Zambia have been the hardest hit, with 2.3 million people affected as a result of the drought experienced during the 2018/19 growing season. Recently, some parts of the country experienced extensive flooding, which submerged agricultural land.

The magnitude of the problem in this part of the world has reached unprecedented levels, creating a threat to peace, security and stability. At the centre of this catastrophe are the small-scale farmers.

Small-scale farmers in this part of the world are critical because they grow food for household consumption, as well generate income for their local communities.

It is against this backdrop that agricultural biotechnology is gaining support from researchers and small-scale farmers who are struggling to recover from floods and droughts. The most significant advantages of genetically modified (GM) crops to small-scale farmers include environmental protection,boosting food production andsustaining rural livelihoods.

In a telephone interview, Sunday Chileya, a smal-lscale farmer based in the northern part of Zambia, expressed worry over food security as a result of the floods that have wiped out his entire field.

I dont know how I am going to feed my family because everything that I planted has gone, Chileya said.

Chileya, who has some basic knowledge of agricultural biotechnology, said the adoption of the technology was the only solution, owing to recurring floods and droughts that have led to crop failure.

I have an idea of what agricultural biotechnology is and the benefits, so why not promote it to help farmers like me? he asked.

Chileya pointed out that there is need to promote the adoption of the technology if small-scale farmers like him are to continue surviving

The climate keeps changing and so should our ways of farming so that we can survive the effects of climate change, Chileya said.

Experts such as Dr. Kalaluka Munyinda, a University of Zambia (UNZA) lecturer and researcher, say agricultural biotechnology is a significant technology that will help small-scale farmers who have been adversely affected by climate change.

Agricultural biotechnology is safe, he said. We are now experiencing extreme events when it comes to the weather and we can use this technology to develop crop varieties that will withstand any weather pattern.

In order to adapt to and mitigate the devastating impact of climate change, there is a need to encourage the use of agricultural biotechnology, Munyinda said.

We are now experiencing situations where pests and diseases are appearing whether its warm or cold and they are spreading rapidly, Munyinda said.

He emphasized that agricultural biotechnology has significant advantages, contrary to the fears that have been created around the technology.

You see as result of using this technology the use of pesticides harmful to our environment is reduced, Munyinda said, noting that other biotech crops will reduce the use of nitrogen fertilizers that contribute to a rise in greenhouse gases.

He reiterated that small-scale farmers are on the receiving hand of climate change.

Small-scale farmers feed us, he said, adding that 90 percent of the maize we consume is grown by small-scale farmers. So if they get affected we wont eat.

He said the Department of Crop Science at the University of Zambia has been working on maize, finger millet, cowpea and beans using biotechnology and he is hopeful that these will benefit small-scale farmers.

Benedict Tembo, an environmental reporter and editor at the Zambia Daily Mail, said agricultural biotechnology has benefits, contrary to the conspiracies peddled by certain groups with unknown agendas.

Fears that agricultural biotechnology is harmful are totally unfounded, he said. Right now, our region is facing the brunt of climate change and there is need to utilize technology that will help our farmers.

Tembo pointed out that Zambia and some other African countries are missing out on an opportunity to introduce pest-resistant Bt cotton, for example, to fight the pests and diseases that are prevalent in Zambia and other countries across the continent.

Agricultural biotechnology increases productivity, which means small-scale farmers will be able to take care of their families and strengthen their financial capacity, he said.

Tembocalled on journalists, who are on the frontlines in disseminating information to people, to report accurately on the benefits of agricultural biotechnology.

An enlightened journalist is an asset to society, which looks up to him/her for the provision of quality, accurate and timely information on the demystification of myths around biotechnology, he said.

Image: Shutterstock

Read more here:
African farmers yearn for biotechnology in the face of climate change - Alliance for Science

The 33 rating InvestorsObserver gives to REDHILL BIOPHAR/S ADR (RDHL) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 23 percent of stocks in the Biotechnology industry, RDHLs 33 overall rating means the stock scores better than 33 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 33 means the stock is more attractive than 33 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

REDHILL BIOPHAR/S ADR (RDHL) stock has risen 3.51% while the S&P 500 is down -1.37% as of 11:31 AM on Tuesday, Feb 25. RDHL has gained $0.16 from the previous closing price of $4.70 on volume of 405,326 shares. Over the past year the S&P 500 is up 13.79% while RDHL is down -37.56%. RDHL earned $0.26 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 18.71.

To see the top 5 stocks in Biotechnology click here.

See the original post here:
How Does REDHILL BIOPHAR/S ADR (RDHL) Stock Compare to Other Stocks in Biotechnology? - InvestorsObserver

LogicBio Therapeutics Inc (LOGC) is near the bottom in its industry group according to InvestorsObserver. LOGC gets an overall rating of 35. That means it scores higher than 35 percent of stocks. LogicBio Therapeutics Inc gets a 23 rank in the Biotechnology industry. Biotechnology is number 54 out of 148 industries.

Click Here to get the full Stock Score Report on LogicBio Therapeutics Inc (LOGC) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 35 means the stock is more attractive than 35 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

LogicBio Therapeutics Inc (LOGC) stock is up 14.53% while the S&P 500 is down -0.34% as of 11:07 AM on Thursday, Jan 23. LOGC is up $1.11 from the previous closing price of $7.64 on volume of 206,086 shares. Over the past year the S&P 500 has risen 25.45% while LOGC is up 10.34%. LOGC lost -$2.49 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the original post here:
Is LogicBio Therapeutics Inc (LOGC) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

GOTHENBURG, Sweden, Dec. 19, 2019 /PRNewswire/ -- Getinge announces today an agreement to acquire 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V. Applikon Biotechnology B.V. is a leading company in the fast growing area of advanced bioreactor systems for biopharmaceutical production and research, with an annual net sales of approximately SEK 450 M.

"Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which will be a positive addition to Getinge's existing offer towards the biopharma segment, the fastest growing area within Life Science," says Mattias Perjos, President & CEO Getinge. "This deal further broadens our position within solutions for efficient, safe and contamination-free research and production processes."

Applikon Biotechnology B.V. is leading in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as wellasenzymes and bio-plasticsfor industrial biotechnology. The value of the global bioreactor market is estimated to be SEK 10 B with an expected growth rate 2019-2024 of approximately 10% per year. Applikon Biotechnology B.V. is a privately-held company, founded in 1973 and has its head office in Delft, The Netherlands. The company employs approximately 180 employees worldwide and works mainly through a global distribution network.

"Through Applikon Biotechnology B.V., Getinge will be able to offer customers better solutions and knowledge covering the entire process frominitial screening to full-scale production, using a fully scalable platform," says Arthur Oudshoorn, CEO of Applikon Biotechnology B.V.. "Getinge's global footprint will substantially strengthen our access to the market and further accelerate Applikon's growth."

Getinge will acquire all outstanding shares in Applikon Biotechnology B.V. and will pay approximately SEK 840 M (EUR 80 M) in cash on closing for 100 % of the shares. In addition, a maximum earn out of approximately SEK 630 M (EUR 60 M) can be paid out in 2021-2022 if agreed earnings performance is achieved in 2020-2021. The acquisition will be financed through debt and the net debt to EBITDA ratio is expected to be impacted by 0.2x at closing of deal in the first quarter of 2020. The integration will be stepwise with full effect from 2022. Getinge expects no material integration costs in 2020-2021.

Long-term, Applikon Biotechnology B.V. is expected to bring a material contribution to Getinge's Life Science business area in terms of net sales and EBITA. Getinge's Life Science business performed SEK 2.3 B in net sales and SEK 293 M in EBITA Q4 2018-Q3 2019. For Getinge, the acquisition is not expected to have a material impact on operating profit and earnings per share as of 2020. The acquisition broadens Getinge's position further within solutions for efficient, safe and contamination-free research and production processes in the biopharma segment.

The transaction is subject to, and conditional upon, the employee consultation obligations under the Works Council Act (Wet op de ondernemingsraden) and the SER Merger Code (SER-besluit Fusiegedragsregels 2015) in the Netherlands having been completed and closing is conditional upon customary closing conditions. The deal is expected to be finalized in the first quarter of 2020.

Deutsche Bank is Getinge's exclusive financial advisor in the acquisition process and the committed debt financing for the transaction is provided by SEB. NautaDutilh is Getinge's leading legal advisor in the transaction.

For more information about Applikon Biotechnology B.V.: http://www.applikon-biotechnology.com

Getinge invites to a conference call

Getinge invites to a conference call hosted by Getinge's President & CEO Mattias Perjos and CFO Lars Sandstrm on December 19, 2019, at 12:00 CET. Please see dial in details below to join the conference:

SE: +46-8-566-426-51UK +44-333-300-0804US +1-855-857-0686

Pin code: 44859140#

During the telephone conference a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/2019-dec-press-conference

Alternatively, use the following link to download the presentation: https://www.getinge.com/int/about-us/investors/reports-presentations.

This information is information that Getinge AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET on December 19, 2019.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

Media contact:Lars Mattson, Head of Investor RelationsTel: +46-(0)10-335-0043Email: lars.mattsson@getinge.com

Jeanette Hedn Carlsson, EVP Communication & AcademyTel: +46-(0)10-335-1003Email: jeanette.hedencarlsson@getinge.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-to-acquire-applikon-biotechnology-b-v--a-leading-company-in-the-fast-growing-area-of-bioreac,c2995282

The following files are available for download:

SOURCE Getinge

See more here:
Getinge to Acquire Applikon Biotechnology BV, A Leading Company in the Fast Growing Area of Bioreactor Systems - PRNewswire

HOLON, Israel, Dec. 20, 2019 /PRNewswire/ --Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI). Compugen's addition to the NBI will become effective prior to market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on the NASDAQ Stock Market (NASDAQ) that are classified as either Biotechnology or Pharmaceuticals according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility criteria, such as an average daily trading volume and minimum market capitalization. The NBI is re-ranked each year and is calculated under a modulated capitalization-weighted methodology. Additionally, the NBI serves as the basis for the Blackrock iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), the largest ETF that tracks this index directly. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

To view the NBI and its historical data, please visit https://www.nasdaq.com/market-activity/index/nbi.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered computationally, including T cell immune checkpoints and additional early-stage immune-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and describe opinions about possible future events including the addition of Compugen to the NASDAQ Biotechnology Index (NASDAQ: ^NBI). These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to advance through clinical development or receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:

Elana HolzmanDirector, Investor Relations and Corporate CommunicationsCompugen Ltd.Email: elanah@cgen.com Tel: +972 (3) 765-8124

Investor Relations contact:

Bob YedidLifeSci Advisors, LLCEmail: bob@lifesciadvisors.com Tel: +1 (646) 597-6989

View original content:http://www.prnewswire.com/news-releases/compugen-added-to-the-nasdaq-biotechnology-index-300978219.html

SOURCE Compugen Ltd.

See the rest here:
Compugen Added to the NASDAQ Biotechnology Index - P&T Community

Event organisers in Hyderabad India which was completely based on the development of biotechnology sector in both Switzerland in India and New Zealand being one of the part of this event as a partner country is expected to host the event with the emerging Technologies and the promotion of certain investment which should be made towards the biotechnology sector and this event was the flagship event known as bi Asia which will be conducted during the month of February in the path of biotechnology industry and the theme will be for today for tomorrow which will promote the various initiatives which need to be taken care to have a better tomorrow and this when will be a platform to deliver the various Technologies we should be promoted and the partnership SMIT should be there to promote the various stakeholders and a platform will be divided to every company and to every student to showcase their talent and to showcase their product and services which are developed for the need of biotechnology in Healthcare sector in both the countries and this water services for the biotechnology Industries will stand up in certain way where the investors will find a need to invest them in their product and to show trust words that particular entrepreneur and having a good feedback from the various visitors now there would be a lot of fuel towards investment decisions including the example of Swiss pharma company lonza which will be participating in the event of Hyderabad setting up the various operations in the country. The reason for choosing Switzerland as a partner country has the various agenda of the development of India and Switzerland both in terms of innovation and startup ecosystem which could promote their partner country in such a way that there would be the ease of doing business for the policies and this will be done to attract the various retain talent which could be a very strong hold for the Healthcare and Biotechnology sector including the promotion of Life Science and just will be done in Telangana to promote the innovation and entrepreneurship in certain areas.

Continue reading here:
Biotechnology in Switzerland Today for tomorrow - Global Market Research